Abstract
Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to the management of patients with AF. Anticoagulation with warfarin is the current standard of care for stroke prevention in these patients, despite the need for close monitoring. Aspirin alone is not as effective. Warfarin is recommended for patients with AF and valvular disease or with AF and one or more stroke risk factors. Other novel anticoagulants and antiplatelet combinations are under investigation. Curative procedures for AF are possible, but their long-term safety and effect on stroke risk are unknown.
| Original language | English |
|---|---|
| Journal | Cleveland Clinic Journal of Medicine |
| Volume | 72 |
| Issue number | SUPPL.1 |
| DOIs | |
| State | Published - 2004 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Stroke prevention in atrial fibrillation : Current anticoagulation management and future directions. / Fitzgerald, Benjamin T.; Lawrence Cohn, Steven; Klein, Allan L.
In: Cleveland Clinic Journal of Medicine, Vol. 72, No. SUPPL.1, 2004.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Stroke prevention in atrial fibrillation
T2 - Current anticoagulation management and future directions
AU - Fitzgerald, Benjamin T.
AU - Lawrence Cohn, Steven
AU - Klein, Allan L.
PY - 2004
Y1 - 2004
N2 - Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to the management of patients with AF. Anticoagulation with warfarin is the current standard of care for stroke prevention in these patients, despite the need for close monitoring. Aspirin alone is not as effective. Warfarin is recommended for patients with AF and valvular disease or with AF and one or more stroke risk factors. Other novel anticoagulants and antiplatelet combinations are under investigation. Curative procedures for AF are possible, but their long-term safety and effect on stroke risk are unknown.
AB - Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to the management of patients with AF. Anticoagulation with warfarin is the current standard of care for stroke prevention in these patients, despite the need for close monitoring. Aspirin alone is not as effective. Warfarin is recommended for patients with AF and valvular disease or with AF and one or more stroke risk factors. Other novel anticoagulants and antiplatelet combinations are under investigation. Curative procedures for AF are possible, but their long-term safety and effect on stroke risk are unknown.
UR - http://www.scopus.com/inward/record.url?scp=84884549179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884549179&partnerID=8YFLogxK
U2 - 10.3949/ccjm.72.Suppl_1.S24
DO - 10.3949/ccjm.72.Suppl_1.S24
M3 - Article
AN - SCOPUS:84884549179
VL - 72
JO - Cleveland Clinic Journal of Medicine
JF - Cleveland Clinic Journal of Medicine
SN - 0891-1150
IS - SUPPL.1
ER -